Tempus AI to Buy Personalis for 1.5 Billion Dollars

Tempus AI announced an all-stock acquisition of Personalis to integrate advanced cancer testing into its precision medicine portfolio. The deal provides access to technology for tracking tumor DNA and is expected to close by early 2027.